Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells $1,065,346.49 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 42,461 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $25.09, for a total transaction of $1,065,346.49. Following the sale, the director directly owned 49,124 shares of the company’s stock, valued at $1,232,521.16. This represents a 46.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Stoke Therapeutics Stock Down 2.0%

STOK opened at $29.90 on Friday. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $32.40. The company has a 50-day simple moving average of $20.63 and a 200 day simple moving average of $13.67. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of 35.18 and a beta of 1.24.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The business had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $31.51 million. Sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on STOK. Wedbush boosted their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Chardan Capital reissued a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Stoke Therapeutics in a research note on Wednesday. Finally, BTIG Research set a $28.00 target price on Stoke Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $25.57.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. raised its holdings in Stoke Therapeutics by 67.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 900,272 shares of the company’s stock valued at $21,156,000 after buying an additional 362,299 shares during the last quarter. Corient Private Wealth LLC acquired a new stake in Stoke Therapeutics during the 2nd quarter valued at approximately $7,489,000. Osaic Holdings Inc. increased its position in Stoke Therapeutics by 263.3% during the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after purchasing an additional 5,427 shares during the period. Tower Research Capital LLC TRC increased its position in Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. Finally, Opaleye Management Inc. increased its position in Stoke Therapeutics by 87.4% during the 2nd quarter. Opaleye Management Inc. now owns 562,120 shares of the company’s stock valued at $6,380,000 after purchasing an additional 262,120 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.